1 Big Pharma Leaps Past Hurdle

Earlier this week, drugmaker Sanofi (NYSE: SNY  ) won approval for its multiple sclerosis treatment Lemtrada in the European Union. While the drug has yet to get the green light in the U.S., it is a key addition to Sanofi's multiple sclerosis lineup, which also includes the oral medication Aubagio. But can the company compete with Biogen (NASDAQ: BIIB  ) and its recently launched MS medication Tecfidera? Analysts David Williamson and Max Macaluso discuss this market in the following video.

9 rock-solid dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Editor's note: At 6:36, the speaker incorrectly states that Sanofi had a partnership with Rigel Pharmaceuticals. The Fool regrets the error.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 03, 2013, at 12:55 PM, ikkyu2 wrote:

    Lemtrada reduces disability, the only MS drug shown to do so, and requires only 6 infusions: 3 in one week at therapy start, 3 in one week at therapy end a year later.

    Initial profits from the drug will be diverted to paying dividends for a warrant called GCVRZ because Sanofi and Genzyme could not agree on the drug's value during the former's acquisition of the latter.

Add your comment.

DocumentId: 2645352, ~/Articles/ArticleHandler.aspx, 4/18/2014 9:42:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement